TCT Conference 2024 - Safety and efficacy outcomes of transcatheter tricuspid valve replacement (TTVR) compared to optimal medical therapy for patients with severe tricuspid regurgitation (TR).

Dr Susheel Kodali (Columbia University Medical Center, New York, US) joins us onsite at TCT Conference to discuss the findings from the TRISCEND II Trial (NCT04482062; Edwards Lifesciences).

TRISCEND II is a multi-center, prospective, randomized trial designed to evaluate the safety and effectiveness of the Edwards EVOQUE tricuspid valve replacement system as compared to optimal medical therapy alone in patients with severe TR. 1,070 patients were enrolled in the trial and were followed-up at 30 days, 3 months, 6 months, and annually for five years post treatment. The primary outcome measures included TR grade reduction, including KCCQ improvement, NYHA functional class improvement and 6-minute walk test distance improvement, as well as a composite endpoint including all-cause mortality, RVAD implantation or heart transplant, tricuspid valve intervention and heart failure hospitalisations.

One year findings showed that the Edwards EVOQUE system demonstrated superiority in primary endpoints for a patient population with limited treatment options. The Edwards EVOQUE system also led to sustained TR reduction with significant improvements in symptoms, function, and quality of life at one year.

Interview Questions:
1.    What is the reasoning behind the TRISCEND II trial?
2.    What was the study design and patient population?
3.    What were the key findings?
4.    Were there any surprising or unexpected results?
5.    What further study is needed?

Recorded at TCT Conference in Washington, 2024.

Editors: Yazmin Sadik, Jordan Rance
Video Specialist: David Ben-Harosh, Oliver Miles

Support: This is an independent interview produced by Radcliffe Cardiology.